Citi Pharma has partnered with Xin Weisheng to build an advanced antibiotic production facility in Pakistan, aiming to improve access to essential medicines and reduce reliance on imported drugs. The company said the new site will focus on manufacturing sterile, high-potency antibiotics like meropenem and piperacillin-tazobactam using automated, aseptic production lines.

The new facility, expected to begin commercial production in 2026, will be capable of producing both active pharmaceutical ingredients (APIs) and finished dosage forms. Citi Pharma says this investment will strengthen local pharmaceutical infrastructure, contribute to national medicine security, and support the Pakistani government’s goal to increase domestic manufacturing of critical therapies.

Xin Weisheng, a subsidiary of the Weisheng Group, is providing technical expertise to support the project. The Chinese firm will contribute advanced process technology, engineering services, and staff training.

“This collaboration represents a significant leap forward in Pakistan’s healthcare sector,” said a Citi Pharma spokesperson.

“By leveraging Xin Weisheng’s technical expertise, we are not only enhancing our own capabilities but also contributing to the broader goal of self-reliance in pharmaceutical manufacturing. Our state-of-the-art facility will be equipped with automated and aseptic production lines, ensuring the highest standards of quality and efficiency.”

The companies say the partnership aims to establish a robust supply chain that can support both domestic and international markets, particularly in the production of antibiotics, where supply gaps have persisted.

“We are proud to partner with Citi Pharma on this landmark initiative,” said a representative from Xin Weisheng.

“Our shared vision of improving access to quality medicines aligns perfectly. We believe that our combined strengths will set new benchmarks in pharmaceutical manufacturing in the region.”

Citi Pharma said the move aligns with its vision to build world-class manufacturing facilities and help improve access to essential medicines across underserved populations.

“This partnership is not just about building a facility; it’s about building a healthier future for millions,” the Citi spokesperson added. “We are committed to making a meaningful impact through innovation, collaboration, and unwavering dedication to quality.”